Project Grant HT9425261E230
- Federal Grant Award Summary Baylor College of Medicine received a $750,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on rat models of lobular carcinoma of the breast. The three-year award period runs from June 1, 2026, through May 31, 2029, and will be performed at Baylor's Houston, Texas facility. This project contributes to the DHA's broader mission of transforming healthcare for service...
- Federal Grant Award Summary Baylor College of Medicine received a $750,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective May 1, 2026 through April 30, 2029. The award supports research into coral-derived biomaterials as a decoy trap mechanism to sequester and eliminate disseminated tumor cells. This three-year initiative leverages Baylor's extensive capabilities in cancer research and biomedical...
- This $1,600,000.00 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at Baylor College of Medicine focused on developing new synthetic lethal combination therapies targeting TopBP1 and the arachidonic acid pathway for breast cancer treatment. The three-year award, with an end date of February 28, 2027, will fund basic, translational, and clinical research aimed at advancing scientific understanding and...
- Federal Project Grant Award Summary Baylor College of Medicine was awarded $480,000 by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2025, for a three-year project through August 31, 2028. The research project, titled "Targeting Cryptic Splicing-Derived Neoantigens in HNRNPM-Dysregulated Triple-Negative Breast Cancer," focuses on identifying and developing immunotherapeutic approaches against novel cancer...
- Federal Grant Award Summary Baylor College of Medicine received a $720,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2028. The grant funds research focused on targeting cryptic splicing-derived neoantigens in HNRNPM-dysregulated triple-negative breast cancer. This research initiative represents the DHA's commitment to advancing biomedical solutions relevant to...
- Baylor College of Medicine will use a $1.56 million project grant from the Defense Health Agency to research germline variants and population-wide breast cancer risk. The grant was awarded on February 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). Through this four-year award, Baylor College of Medicine will investigate medical solutions for breast cancer through innovative and impactful research aimed at transforming health care for service members and the...
- The federal Project Grant award of $1,597,224.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program to support the research project "BCL-XL IN BREAST CANCER METASTASIS AND THERAPY" at Baylor College of Medicine in Houston, Texas. The award, with a performance period from August 1, 2024 to July 31, 2027, will fund advanced biomedical research initiatives focused on transforming healthcare for military service...
- This federal Project Grant award of $2,239,998.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Baylor College of Medicine to investigate the progression from ductal carcinoma in situ (DCIS) to invasive basal-like breast cancer driven by the N-RAS gene. The research project aims to advance the understanding of this disease process with the potential to lead to improved diagnostic and treatment approaches. The award...
- Project Grant Award Summary Baylor College of Medicine received a $1.62M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded September 1, 2025, with a completion date of December 14, 2028. The award supports preclinical validation of novel combination therapeutic strategies targeting KRAS and BRAF mutations in colorectal cancer for near-term clinical examination. This research initiative delivers basic and...
- The Baylor College of Medicine will use a $1.6 million Project Grant from the Defense Health Agency to research germline variants and population-wide breast cancer risk. The grant was awarded on February 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). Through basic, applied, and advanced biomedical research, this project aims to transform healthcare for service members and the public by investigating medical solutions for the battlefield and developing...
Baylor College of Medicine received a $500,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for research on rat models of lobular carcinoma of the breast. The award, effective June 1, 2026 through May 31, 2029, supports basic and translational research designed to advance understanding of breast cancer biology and develop innovative medical solutions relevant to military health priorities. The research will be conducted at Baylor's facilities in Houston, Texas, leveraging the institution's substantial capabilities in cancer research, biomarker discovery, and specialized laboratory analysis. This project aligns with the Defense Health Agency's strategic focus on hypothesis-driven oncology research aimed at transforming healthcare for service members and the American public. Baylor College of Medicine's extensive track record in cancer research, including prior Defense Health Agency-funded studies on triple-negative breast cancer and other malignancies, positions the institution to deliver high-quality research outputs and translational findings that may inform therapeutic development and clinical applications for lobular carcinoma of the breast.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $500.0k | 5/20/26 |